Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 5/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | PER2 | O15055 | 1/20 | 0.35 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831825 | 0.94 | CYP2C8 (0.39) | EDNRBCYP2C8PPARGTP53RXFP1 | |
| SCHEMBL862397 | 0.92 | TP53 (0.44) | EDNRBCYP2C8PPARGTP53RXFP1 | |
| SCHEMBL862217 | 0.92 | PPARG (0.43) | EDNRBCYP2C8PPARGTP53SCN9A | |
| SCHEMBL10257585 | 0.91 | PPARG (0.40) | CYP2C8PPARGSCN9ASCN5APTGDR2 | |
| SCHEMBL831243 | 0.89 | EDNRB (0.43) | EDNRBPPARGTP53RXFP1SCN9A | |
| SCHEMBL862182 | 0.88 | CYP2C8 (0.40) | EDNRBCYP2C8PPARGSCN9APER2 | |
| SCHEMBL831268 | 0.88 | CYP2C8 (0.45) | CYP2C8PPARGSCN9AMAPTPTGDR2 | |
| SCHEMBL831198 | 0.88 | CYP2C8 (0.43) | CYP2C8PPARGRXFP1SCN9ASCN5A | |
| SCHEMBL12673689 | 0.88 | CYP2C8 (0.49) | EDNRBCYP2C8TP53RXFP1PTGDR2 | |
| SCHEMBL831053 | 0.88 | CYP2C8 (0.41) | CYP2C8PPARGSCN9APTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | EDNRB 1094/4885CYP2C8 847/4885PPARG 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.